Risk factors for SARS-CoV-2 pneumonia among renal transplant recipients in Omicron pandemic—a prospective cohort study DOI Creative Commons
Sai Zhang, Xiang Ding,

Chunmi Geng

и другие.

Virology Journal, Год журнала: 2024, Номер 21(1)

Опубликована: Дек. 4, 2024

The coronavirus disease (COVID-19) pandemic is a global health emergency, and SARS-CoV-2 pneumonia poses significant challenges to systems worldwide. Renal transplant recipients (RTRs) are special group more vulnerable viral pneumonia. However, few studies have elucidated the risk factors of in RTRs infected with COVID-19. This study aimed build prediction model for among based on demographic clinical information. We conducted prospective cohort 383 (age ≥ 18 years) diagnosed COVID-19 from December 21, 2022, March 26, 2023. Patients' information was collected through questionnaire survey combined electronic medical records. A stepwise logistic regression established test predictors assessed diagnostic performance by calculating area under curve (AUC) receiver operating characteristic (ROC) calibration using Hosmer-Lemeshow (HL) goodness-of-fit test. Our showed that incidence 31.1%. Older age (OR = 2.08-3.37,95%CI:1.05-7.23), shorter post-transplantation duration 0.92,95% CI: 0.87,0.99), higher post-transplant Charlson Comorbidity Index (CCI) 1.84, 95%CI: 1.14,2.98), pulmonary infection history 3.44, 1.459, 8.099, P 0.005), fatigue 2.11, 1.14, 3.90), cough 2.03, 1.08, 3.81), lower estimated glomerular filtration rate (eGFR) at diagnosis 0.98, 95%CI:0.97,0.99) predicted good Chi-Square 10.832 (P > 0.05) AUC 0.839 < 0.001). high RTRs, we built patients' characteristics. can help identify inform timely, targeted, effective prevention intervention efforts.

Язык: Английский

Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation DOI Creative Commons
Dong‐Sik Kim,

Young‐In Yoon,

Beom Kyung Kim

и другие.

Hepatology International, Год журнала: 2024, Номер 18(2), С. 299 - 383

Опубликована: Фев. 28, 2024

Liver transplantation is a highly complex and challenging field of clinical practice. Although it was originally developed in western countries, has been further advanced Asian countries through the use living donor liver transplantation. This method only available option many Asia-Pacific region due to lack deceased organ donation. As result this situation, there growing need for guidelines that are specific region. These provide comprehensive recommendations evidence-based management throughout entire process transplantation, covering both In addition, development these collaborative effort between medical professionals from various allowed inclusion diverse perspectives experiences, leading more effective set guidelines.

Язык: Английский

Процитировано

15
The epidemiology of invasive fungal infections in transplant recipients DOI Creative Commons

Dorra Elhaj Mahmoud,

Anaïs Hérivaux, Florent Morio

и другие.

Biomedical Journal, Год журнала: 2024, Номер 47(3), С. 100719 - 100719

Опубликована: Апрель 4, 2024

Transplant patients, including solid-organ transplant (SOT) and hematopoietic stem cell (HSCT) recipients, are exposed to various types of complications, particularly rejection. To prevent these outcomes, recipients commonly receive long-term immunosuppressive regimens that in turn make them more susceptible a wide array infectious diseases, notably those caused by opportunistic pathogens. Among these, invasive fungal infections (IFIs) remain major cause mortality morbidity both SOT HSCT recipients. Despite the continuing improvement early diagnostics treatments IFIs, management patients is still complicated. Here, we provide an overview concerning most recent trends epidemiology IFIs describing prominent yeasts molds species involved, timing post-transplant risk factors associated with their occurrence weak populations. We also give special emphasis into basic research advances field recently suggested role global prophylactic regimen orchestrating biological disturbances organism conditioning emergence adapted strains particular physiological profiles patients.

Язык: Английский

Процитировано

10
Pneumocystis Jirovecii Pneumonia in Two Immunosuppressed Non-HIV Infected Patients: A Clinical and Therapeutic Analysis DOI Creative Commons

Weiran Li,

Hua Mao, Jin Guo

и другие.

Infection and Drug Resistance, Год журнала: 2025, Номер Volume 18, С. 285 - 295

Опубликована: Янв. 1, 2025

Pneumocystis jirovecii pneumonia (PJP) is an opportunistic fungal infection that often occurs secondary to human immunodeficiency virus (HIV) infection.However, for non-HIV immunocompromised patients, such as those undergoing novel immunosuppressive treatments manage malignancies, organ transplants, or connective tissue diseases, PJP emerging increasing threat.The clinical manifestations of in HIV-infected and non-HIV-infected patients differ significantly.In progresses rapidly challenging diagnose, resulting severe respiratory failure a poor prognosis.We describe lymphocytopenia two women who were recently treated with methotrexate, tacrolimus, corticosteroids therapy following adjuvant chemotherapy breast cancer kidney transplantation.The initial examination included high-resolution chest CT indicating atypical pneumonia, treatment was initiated trimethoprim -sulfamethoxazole oxygen support.Subsequently, bronchoscopy bronchoalveolar lavage mNGS detected jirovecii.After 3 weeks cotrimoxazole, the recovered significantly their condition stable.

Язык: Английский

Процитировано

1
Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in patients with systemic rheumatic diseases receiving moderate-to high-dose glucocorticoids DOI
Shin‐ichiro Ohmura,

Takayuki Masui,

Toshitaka Yukishima

и другие.

Respiratory Investigation, Год журнала: 2024, Номер 62(6), С. 1195 - 1201

Опубликована: Окт. 22, 2024

Язык: Английский

Процитировано

1
Proceedings of the 28th Annual Congress of the International Liver Transplantation Society DOI
Johns Shaji Mathew, Alexandra Shingina, Mohammad Qasim Khan

и другие.

Liver Transplantation, Год журнала: 2024, Номер 30(5), С. 544 - 554

Опубликована: Янв. 19, 2024

The 2023 Joint International Congress of the Liver Transplantation Society (ILTS), European and Intestine Transplant Association (ELITA), Intensive Care Group Europe (LICAGE) held in Rotterdam, Netherlands, marked a significant recovery milestone for liver transplant community after COVID-19. With 1159 participants surge abstract submissions, event focused on “Liver Disorders Transplantation: Innovations Evolving Indications.” This conference report provides comprehensive overview key themes discussed during event, encompassing Hepatology, Anesthesia Critical Care, Acute Failure, Infectious Disease, Immunosuppression, Pediatric Transplantation, Living Donor Oncology, Surgical Approaches, Machine Perfusion. congress provided platform extensive discussions wide range topics, reflecting continuous advancements collaborative efforts within community.

Язык: Английский

Процитировано

0
Strengths and limitations of molecular diagnostics for Pneumocystis jirovecii pneumonia DOI
Lottie Brown, Alexandre Alanio, Mario Cruciani

и другие.

Expert Review of Molecular Diagnostics, Год журнала: 2024, Номер unknown, С. 1 - 13

Опубликована: Ноя. 18, 2024

While

Язык: Английский

Процитировано

0
Risk factors for SARS-CoV-2 pneumonia among renal transplant recipients in Omicron pandemic—a prospective cohort study DOI Creative Commons
Sai Zhang, Xiang Ding,

Chunmi Geng

и другие.

Virology Journal, Год журнала: 2024, Номер 21(1)

Опубликована: Дек. 4, 2024

The coronavirus disease (COVID-19) pandemic is a global health emergency, and SARS-CoV-2 pneumonia poses significant challenges to systems worldwide. Renal transplant recipients (RTRs) are special group more vulnerable viral pneumonia. However, few studies have elucidated the risk factors of in RTRs infected with COVID-19. This study aimed build prediction model for among based on demographic clinical information. We conducted prospective cohort 383 (age ≥ 18 years) diagnosed COVID-19 from December 21, 2022, March 26, 2023. Patients' information was collected through questionnaire survey combined electronic medical records. A stepwise logistic regression established test predictors assessed diagnostic performance by calculating area under curve (AUC) receiver operating characteristic (ROC) calibration using Hosmer-Lemeshow (HL) goodness-of-fit test. Our showed that incidence 31.1%. Older age (OR = 2.08-3.37,95%CI:1.05-7.23), shorter post-transplantation duration 0.92,95% CI: 0.87,0.99), higher post-transplant Charlson Comorbidity Index (CCI) 1.84, 95%CI: 1.14,2.98), pulmonary infection history 3.44, 1.459, 8.099, P 0.005), fatigue 2.11, 1.14, 3.90), cough 2.03, 1.08, 3.81), lower estimated glomerular filtration rate (eGFR) at diagnosis 0.98, 95%CI:0.97,0.99) predicted good Chi-Square 10.832 (P > 0.05) AUC 0.839 < 0.001). high RTRs, we built patients' characteristics. can help identify inform timely, targeted, effective prevention intervention efforts.

Язык: Английский

Процитировано

0